Trade BioMarin Pharmaceutical Inc - BMRN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.58 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biomarin Pharmaceutical Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 111.08 |
Open* | 110.19 |
1-Year Change* | 23.49% |
Day's Range* | 109.73 - 111.54 |
52 wk Range | 70.73-117.77 |
Average Volume (10 days) | 1.49M |
Average Volume (3 months) | 30.89M |
Market Cap | 20.69B |
P/E Ratio | 281.93 |
Shares Outstanding | 185.85M |
Revenue | 2.01B |
EPS | 0.39 |
Dividend (Yield %) | N/A |
Beta | 0.36 |
Next Earnings Date | Feb 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 110.26 | -0.18 | -0.16% | 110.44 | 111.55 | 109.28 |
Feb 7, 2023 | 111.08 | 0.35 | 0.32% | 110.73 | 111.42 | 109.56 |
Feb 6, 2023 | 111.76 | 0.78 | 0.70% | 110.98 | 112.83 | 109.93 |
Feb 3, 2023 | 111.72 | -0.63 | -0.56% | 112.35 | 113.68 | 111.21 |
Feb 2, 2023 | 112.62 | -3.05 | -2.64% | 115.67 | 116.34 | 111.50 |
Feb 1, 2023 | 116.50 | 2.14 | 1.87% | 114.36 | 116.68 | 113.19 |
Jan 31, 2023 | 115.12 | 1.18 | 1.04% | 113.94 | 115.38 | 113.94 |
Jan 30, 2023 | 114.47 | -1.80 | -1.55% | 116.27 | 116.93 | 114.14 |
Jan 27, 2023 | 116.79 | 1.47 | 1.27% | 115.32 | 117.56 | 115.32 |
Jan 26, 2023 | 116.58 | 1.07 | 0.93% | 115.51 | 116.94 | 114.46 |
Jan 25, 2023 | 115.45 | 1.60 | 1.41% | 113.85 | 116.29 | 113.84 |
Jan 24, 2023 | 113.39 | 3.30 | 3.00% | 110.09 | 113.79 | 110.09 |
Jan 23, 2023 | 110.98 | 1.71 | 1.56% | 109.27 | 111.38 | 108.74 |
Jan 20, 2023 | 110.47 | 1.35 | 1.24% | 109.12 | 110.86 | 108.49 |
Jan 19, 2023 | 108.78 | -1.10 | -1.00% | 109.88 | 109.96 | 108.60 |
Jan 18, 2023 | 110.28 | -0.81 | -0.73% | 111.09 | 111.73 | 110.15 |
Jan 17, 2023 | 111.36 | 0.36 | 0.32% | 111.00 | 112.79 | 109.88 |
Jan 13, 2023 | 112.27 | 1.12 | 1.01% | 111.15 | 114.58 | 110.75 |
Jan 12, 2023 | 112.91 | 2.89 | 2.63% | 110.02 | 113.43 | 108.97 |
Jan 11, 2023 | 110.68 | -0.47 | -0.42% | 111.15 | 112.46 | 108.79 |
BioMarin Pharmaceutical Inc Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
Revenue | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
Cost of Revenue, Total | 209.62 | 241.786 | 315.264 | 359.466 | 524.272 | 470.515 |
Gross Profit | 907.234 | 1071.86 | 1175.95 | 1344.58 | 1336.18 | 1375.76 |
Total Operating Expense | 1920.28 | 1328.35 | 1614.74 | 1804.51 | 1897.22 | 1928.62 |
Selling/General/Admin. Expenses, Total | 472.976 | 565.167 | 610.014 | 675.665 | 737.784 | 760.923 |
Research & Development | 661.905 | 610.753 | 696.328 | 715.007 | 628.116 | 628.793 |
Depreciation / Amortization | 30.2 | 36.2 | 30.3 | 53.5 | 62.2 | 61.9 |
Interest Expense (Income) - Net Operating | 3.617 | -10.831 | -5.661 | 5.259 | -0.115 | -1.548 |
Unusual Expense (Income) | 599.118 | -125 | -50 | -25 | -59.495 | 0 |
Other Operating Expenses, Total | -57.153 | 10.271 | 18.491 | 20.608 | 4.458 | 8.033 |
Operating Income | -803.429 | -14.7 | -123.524 | -100.457 | -36.765 | -82.341 |
Interest Income (Expense), Net Non-Operating | -32.55 | -29.145 | -21.386 | -1.299 | -12.705 | -4.855 |
Other, Net | 4.929 | 7.97 | 2.205 | 6.945 | 7.148 | 11.846 |
Net Income Before Taxes | -831.05 | -35.875 | -142.705 | -94.811 | -42.322 | -75.35 |
Net Income After Taxes | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Net Income Before Extra. Items | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Net Income | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Income Available to Common Excl. Extra. Items | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Income Available to Common Incl. Extra. Items | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Diluted Net Income | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Diluted Weighted Average Shares | 165.985 | 174.427 | 177.061 | 179.039 | 191.678 | 182.852 |
Diluted EPS Excluding Extraordinary Items | -3.79679 | -0.4285 | -0.43607 | -0.1332 | 0.0238 | -0.37189 |
Diluted Normalized EPS | -1.45063 | -0.89431 | -0.61962 | -0.22396 | -0.17796 | -0.37189 |
Total Extraordinary Items | -42.3 | 0 | 854.539 | 3.92 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
Revenue | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
Cost of Revenue, Total | 120.166 | 127.062 | 103.537 | 119.75 | 116.965 |
Gross Profit | 365.864 | 374.631 | 305.205 | 330.06 | 402.394 |
Total Operating Expense | 460.944 | 490.021 | 461.961 | 515.69 | 382.032 |
Selling/General/Admin. Expenses, Total | 174.318 | 184.161 | 183.333 | 217.563 | 194.619 |
Research & Development | 148.725 | 161.107 | 157.869 | 161.092 | 160.836 |
Depreciation / Amortization | 15.4 | 15.5 | 15.4 | 15.6 | 15.6 |
Unusual Expense (Income) | 0 | 0 | 0 | 0 | -108 |
Other Operating Expenses, Total | 2.335 | 2.191 | 1.822 | 1.685 | 2.012 |
Operating Income | 25.086 | 11.672 | -53.219 | -65.88 | 137.327 |
Interest Income (Expense), Net Non-Operating | -2.716 | 0.479 | -1.866 | -0.752 | -1.986 |
Other, Net | 0.858 | 2.005 | 8.925 | 0.058 | -1.154 |
Net Income Before Taxes | 23.228 | 14.156 | -46.16 | -66.574 | 134.187 |
Net Income After Taxes | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Net Income Before Extra. Items | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Net Income | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Income Available to Common Excl. Extra. Items | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Income Available to Common Incl. Extra. Items | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Diluted Net Income | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Diluted Weighted Average Shares | 184.365 | 185.427 | 183.214 | 183.56 | 194.886 |
Diluted EPS Excluding Extraordinary Items | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.61984 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.12096 |
Total Extraordinary Items | 3.92 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 1421.79 | 2207.14 | 2056.22 | 1942.14 | 2342.22 | 2274.39 |
Cash and Short Term Investments | 789.677 | 1395.97 | 1084.31 | 753.807 | 1065.39 | 1013.88 |
Cash & Equivalents | 408.33 | 598.028 | 493.982 | 437.446 | 649.158 | 587.276 |
Short Term Investments | 381.347 | 797.94 | 590.326 | 316.361 | 416.228 | 426.599 |
Total Receivables, Net | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
Accounts Receivable - Trade, Net | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
Total Inventory | 355.126 | 475.775 | 530.871 | 680.275 | 698.548 | 776.669 |
Other Current Assets, Total | 61.708 | 74.036 | 98.403 | 130.657 | 129.934 | 110.442 |
Total Assets | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
Property/Plant/Equipment, Total - Net | 798.768 | 896.7 | 948.682 | 1070.3 | 1089.58 | 1081.88 |
Property/Plant/Equipment, Total - Gross | 1141.36 | 1303.43 | 1421.32 | 1619.4 | 1725.18 | 1802.45 |
Accumulated Depreciation, Total | -342.594 | -406.734 | -472.635 | -549.1 | -635.595 | -720.574 |
Goodwill, Net | 197.039 | 197.039 | 197.039 | 197.039 | 196.199 | 196.199 |
Intangibles, Net | 553.78 | 517.51 | 491.808 | 456.58 | 417.271 | 388.652 |
Long Term Investments | 572.711 | 385.785 | 235.864 | 411.978 | 285.473 | 507.793 |
Other Long Term Assets, Total | 479.601 | 428.947 | 497.52 | 611.997 | 1517.28 | 1554.42 |
Total Current Liabilities | 439.31 | 816.518 | 523.241 | 932.503 | 492.548 | 539.822 |
Payable/Accrued | 198.53 | 161.652 | 208.119 | 240.981 | 191.429 | 193.003 |
Accrued Expenses | 158.926 | 201.601 | 213.03 | 287.878 | 266.254 | 277.059 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 22.478 | 360.949 | 0 | 365.131 | 2.865 | 2.266 |
Other Current Liabilities, Total | 59.376 | 92.316 | 102.092 | 38.513 | 32 | 67.494 |
Total Liabilities | 1257.42 | 1824.46 | 1459.19 | 1567.66 | 1742.02 | 1732.58 |
Total Long Term Debt | 660.761 | 813.521 | 830.417 | 492.946 | 1079.15 | 1081.04 |
Long Term Debt | 660.761 | 813.521 | 830.417 | 486.238 | 1075.15 | 1079.08 |
Deferred Income Tax | 0 | |||||
Other Liabilities, Total | 157.344 | 194.423 | 105.53 | 142.209 | 170.319 | 111.726 |
Total Equity | 2766.27 | 2808.66 | 2967.94 | 3122.38 | 4106 | 4270.74 |
Common Stock | 0.173 | 0.176 | 0.178 | 0.18 | 0.182 | 0.184 |
Additional Paid-In Capital | 4288.11 | 4483.22 | 4669.93 | 4832.71 | 4993.41 | 5191.5 |
Retained Earnings (Accumulated Deficit) | -1520.51 | -1637.55 | -1694.13 | -1720.71 | -861.609 | -925.689 |
Other Equity, Total | -1.505 | -34.463 | -6.113 | 6.638 | -29.867 | 6.116 |
Total Liabilities & Shareholders’ Equity | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
Total Common Shares Outstanding | 172.648 | 175.844 | 178.253 | 179.838 | 181.741 | 183.913 |
Unrealized Gain (Loss) | -2.722 | -1.917 | 3.565 | 3.889 | -1.373 | |
Capital Lease Obligations | 6.708 | 4.006 | 1.96 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 2288.77 | 2357.84 | 2311.57 | 2274.39 | 2394.02 |
Cash and Short Term Investments | 1087.49 | 1123.4 | 1079.48 | 1013.88 | 1056.24 |
Cash & Equivalents | 667.313 | 641.533 | 617.143 | 587.276 | 605.44 |
Short Term Investments | 420.178 | 481.864 | 462.333 | 426.599 | 450.798 |
Total Receivables, Net | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
Accounts Receivable - Trade, Net | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
Total Inventory | 713.929 | 710.975 | 749.406 | 776.669 | 786.356 |
Other Current Assets, Total | 91.249 | 99.046 | 107.751 | 110.442 | 121.283 |
Total Assets | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
Property/Plant/Equipment, Total - Net | 1022.47 | 1026.58 | 1024.79 | 1035.46 | 1039.54 |
Property/Plant/Equipment, Total - Gross | 1679.77 | 1704.7 | 1724.7 | 1756.04 | 1780.71 |
Accumulated Depreciation, Total | -657.296 | -678.126 | -699.915 | -720.574 | -741.167 |
Goodwill, Net | 196.199 | 196.199 | 196.199 | 196.199 | 196.199 |
Intangibles, Net | 405.903 | 394.298 | 388.487 | 388.652 | 374.251 |
Long Term Investments | 321.127 | 350.237 | 466.618 | 507.793 | 462.827 |
Other Long Term Assets, Total | 1570.58 | 1573.35 | 1589.81 | 1600.83 | 1595.86 |
Total Current Liabilities | 430.035 | 443.344 | 514.898 | 539.822 | 490.418 |
Payable/Accrued | 165.001 | 176.073 | 203.321 | 203.467 | 187.81 |
Accrued Expenses | 209.203 | 207.005 | 241.535 | 268.861 | 214.435 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 55.831 | 60.266 | 70.042 | 67.494 | 88.173 |
Total Liabilities | 1643.04 | 1656.93 | 1711.33 | 1732.58 | 1671.39 |
Total Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
Other Liabilities, Total | 136.881 | 136.471 | 118.335 | 113.686 | 100.913 |
Total Equity | 4162.01 | 4241.57 | 4266.15 | 4270.74 | 4391.31 |
Common Stock | 0.183 | 0.183 | 0.184 | 0.184 | 0.185 |
Additional Paid-In Capital | 5010.62 | 5083.83 | 5133.74 | 5191.5 | 5206.29 |
Retained Earnings (Accumulated Deficit) | -844.238 | -831.297 | -867.791 | -925.689 | -804.891 |
Unrealized Gain (Loss) | 2.387 | 1.821 | 1.218 | -1.373 | -9.264 |
Other Equity, Total | -6.941 | -12.967 | -1.204 | 6.116 | -1.002 |
Total Liabilities & Shareholders’ Equity | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
Total Common Shares Outstanding | 182.671 | 183.322 | 183.567 | 183.913 | 184.902 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Cash From Operating Activities | -227.837 | -8.757 | 20.208 | 48.262 | 85.365 | 304.536 |
Cash From Operating Activities | 96.912 | 87.861 | 95.671 | 105.3 | 105.172 | 108.039 |
Deferred Taxes | -228.054 | 44.464 | -68.378 | -82.76 | -888.907 | -15.608 |
Non-Cash Items | 693.791 | 69.923 | 119.546 | 150.662 | 234.417 | 210.151 |
Cash Taxes Paid | 95.857 | 23.895 | 16.676 | 9.726 | 8.977 | 18.153 |
Cash Interest Paid | 8.643 | 8.544 | 11.623 | 8.552 | 12.178 | 10.395 |
Changes in Working Capital | -160.276 | -93.963 | -49.42 | -101.092 | -224.417 | 66.034 |
Cash From Investing Activities | -484.047 | -305.459 | 264.351 | -31.026 | -53.621 | -366.313 |
Capital Expenditures | -148.38 | -199.219 | -144.62 | -163.406 | -137.519 | -119.225 |
Other Investing Cash Flow Items, Total | -335.667 | -106.24 | 408.971 | 132.38 | 83.898 | -247.088 |
Cash From Financing Activities | 727.108 | 507.145 | -388.007 | -74.674 | 181.118 | -0.048 |
Financing Cash Flow Items | -60.057 | -35.427 | -80.542 | -101.198 | -44.638 | -46.203 |
Issuance (Retirement) of Stock, Net | 787.165 | 60.859 | 67.488 | 31.611 | 21.913 | 49.194 |
Foreign Exchange Effects | -3.934 | -3.231 | -0.598 | 0.902 | -1.15 | -0.057 |
Net Change in Cash | 11.29 | 189.698 | -104.046 | -56.536 | 211.712 | -61.882 |
Issuance (Retirement) of Debt, Net | 481.713 | -374.953 | -5.087 | 203.843 | -3.039 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 17.371 | 30.312 | -6.182 | -64.08 | 120.798 |
Cash From Operating Activities | 113.512 | 196.296 | 293.356 | 304.536 | -45.431 |
Cash From Operating Activities | 27.983 | 55.214 | 82.053 | 108.039 | 27.343 |
Deferred Taxes | 3.335 | 1.204 | -12.02 | -15.608 | 4.8 |
Non-Cash Items | 56.553 | 111.414 | 163.355 | 210.151 | -61.68 |
Cash Taxes Paid | 2.998 | 10.159 | 15.531 | 18.153 | 1.316 |
Cash Interest Paid | 1.465 | 5.195 | 6.673 | 10.395 | 1.422 |
Changes in Working Capital | 8.27 | -1.848 | 66.15 | 66.034 | -136.692 |
Cash From Investing Activities | -70.788 | -191.045 | -310.892 | -366.313 | 87.782 |
Capital Expenditures | -28.254 | -54.506 | -74.866 | -119.225 | -30.675 |
Other Investing Cash Flow Items, Total | -42.534 | -136.539 | -236.026 | -247.088 | 118.457 |
Cash From Financing Activities | -24.364 | -13.413 | -14.444 | -0.048 | -25.28 |
Financing Cash Flow Items | -29.097 | -39.112 | -44.829 | -46.203 | -32.949 |
Issuance (Retirement) of Stock, Net | 5.817 | 27.64 | 32.877 | 49.194 | 8.235 |
Issuance (Retirement) of Debt, Net | -1.084 | -1.941 | -2.492 | -3.039 | -0.566 |
Foreign Exchange Effects | -0.205 | 0.537 | -0.035 | -0.057 | 1.093 |
Net Change in Cash | 18.155 | -7.625 | -32.015 | -61.882 | 18.164 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
PRIMECAP Management Company | Investment Advisor | 9.4838 | 17625505 | -52980 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.1613 | 17026106 | 263453 | 2022-09-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 7.9494 | 14773963 | -233100 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3137 | 9875458 | 113895 | 2022-09-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 4.1004 | 7620494 | 0 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 3.0607 | 5688259 | 129970 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8402 | 5278438 | -117928 | 2022-09-30 | LOW |
Viking Global Investors LP | Investment Advisor/Hedge Fund | 2.7437 | 5099164 | 46571 | 2022-09-30 | |
Capital Research Global Investors | Investment Advisor | 2.6563 | 4936740 | 1394 | 2022-09-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 2.2221 | 4129724 | -71509 | 2022-09-30 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 1.9131 | 3555555 | 271555 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.353 | 2514523 | 42707 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.2642 | 2349540 | 223693 | 2021-12-31 | LOW |
Parnassus Investments, LLC | Investment Advisor | 1.2583 | 2338529 | -227551 | 2022-12-31 | LOW |
Barclays Bank PLC | Investment Advisor | 1.1309 | 2101767 | 182659 | 2022-09-30 | MED |
Palo Alto Investors LP | Hedge Fund | 1.0634 | 1976265 | -85108 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.0085 | 1874272 | 348269 | 2022-09-30 | HIGH |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.9306 | 1729432 | 1607478 | 2022-09-30 | HIGH |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 0.924 | 1717310 | 17600 | 2022-09-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7732 | 1437057 | -102057 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.
Equity composition
Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.
Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
Income Statement
- Annual
- Quarterly
News

Markets look for guidance after Powell speech, eyeing US CPI: USD, S&P 500, DAX 40
Us equities try to build appetite to push higher after Powell acknowledges disinflation during his speech
12:34, 8 February 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
15:00, 7 February 2023
Gold Price Forecast: Gold Loses Shine as USD and US Yields Edge Higher
Gold correcting lower on USD comeback. Eyes on Chair Powell to exacerbate Gold downside
12:41, 7 February 2023
Australian Dollar Outlook: AUD/USD bounces back as RBA hikes 25bps
AUS/USD bounces higher as RBA delivers its 9th rate hike
11:28, 7 February 2023
Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields
Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.
14:36, 6 February 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com